학술논문
Long Term, Registry-Based, Prospective, Post-Authorization Safety Study Evaluating Adverse Events of Special Interest in Patients with Highly Active Relapsing Multiple Sclerosis Newly Started on Cladribine Tablets − CLARION
Document Type
Abstract
Author
Source
In Multiple Sclerosis and Related Disorders January 2020 37
Subject
Language
ISSN
2211-0348